Genmab (NASDAQ: GMAB) details DKK 725m share buy-back progress

Rhea-AI Filing Summary

Genmab A/S provides an update on its recently initiated share buy-back program. The company plans to repurchase up to 342,130 shares with a maximum aggregate value of DKK 725 million to meet obligations under its Restricted Stock Unit program, with completion expected by March 31, 2026.

From February 18 to February 20, 2026, Genmab repurchased 23,000, 25,000 and 15,000 shares, respectively, for a total consideration of DKK 115,224,550. Following these transactions, Genmab holds 2,678,851 treasury shares, representing 4.17% of its total share capital and voting rights.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE MONTH OF FEBRUARY 2026

COMMISSION FILE NUMBER 001-38976

Genmab A/S
(Exact name of Registrant as specified in its charter)

Carl Jacobsens Vej 30

2500 Valby

Denmark

+45 70 20 27 28
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  Form 40-F 

This report on Form 6-K shall be deemed to be incorporated by reference in Genmab A/S’s registration statements on Form S-8 (File No. 333-232693, 333-253519, 333-262970, 333-277273, 333-284876 and 333-293505) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit			Description of Exhibit
99.1			Company Announcement Dated February 23, 2026: Transactions in Connection with Share Buy-back Program

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			GENMAB A/S
			BY:			/s/ Anthony Pagano
						Name: Anthony Pagano
						Title: Executive Vice President & Chief Financial Officer

DATE: FEBRUARY 23, 2026

Exhibit 99.1

Transactions in Connection with Share Buy-back Program

Company Announcement

COPENHAGEN, Denmark; February 23, 2026 – Genmab A/S (Nasdaq: GMAB). On February 17, 2026, Genmab announced the initiation of a share buy-back program to repurchase up to 342,130 shares with a maximum aggregate total value of DKK 725 million to honor our commitments under the Restricted Stock Unit program.

The share buy-back program is expected to be completed no later than March 31, 2026.

The following transactions were executed under the program from February 18 to February 20, 2026:

			No. of Shares			Average price (DKK)			Total value (DKK)
February 18, 2026			23,000			1,840.80			42,338,400
February 19, 2026			25,000			1,811.98			45,299,500
February 20, 2026			15,000			1,839.11			27,586,650
Total									115,224,550
Accumulated under the program									115,224,550

Following these transactions, Genmab holds 2,678,851 shares as treasury shares, corresponding to 4.17% of the total share capital and voting rights.

The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Further details on the terms of the share buy-back program can be found in our company announcement no. 05 dated February 17, 2026.

About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 08 Page 1/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

Transactions in Connection with Share Buy-back Program

Contact:    
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby, Denmark Tel: +45 7020 2728
www.genmab.com
Company Announcement no. 08 Page 2/2 CVR no. 2102 3884 LEI Code 529900MTJPDPE4MHJ122

FAQ

What did Genmab (GMAB) disclose in its February 2026 Form 6-K?

Genmab reported transactions under its share buy-back program. Between February 18 and 20, 2026 it repurchased shares for a total of DKK 115,224,550, and now holds 2,678,851 treasury shares, equal to 4.17% of its share capital and voting rights.

What is the size of Genmab’s current share buy-back program?

Genmab’s program allows repurchases of up to 342,130 shares with a maximum aggregate value of DKK 725 million. The program is intended to honor commitments under the company’s Restricted Stock Unit program and is expected to be completed no later than March 31, 2026.

How many Genmab shares were repurchased between February 18 and 20, 2026?

Genmab repurchased 23,000 shares on February 18, 25,000 on February 19, and 15,000 on February 20, 2026. These transactions were executed under its buy-back program and amounted to a total value of DKK 115,224,550 during that three-day period.

What percentage of Genmab’s share capital is held as treasury shares?

After the reported buy-back transactions, Genmab holds 2,678,851 shares as treasury shares. This position corresponds to 4.17% of the company’s total share capital and voting rights, reflecting the cumulative effect of the ongoing share repurchase activity under the program.

Why is Genmab conducting a share buy-back program?

Genmab is repurchasing shares to honor commitments under its Restricted Stock Unit program. Using treasury shares for equity-based compensation helps the company meet obligations to employees while managing share issuance, within a framework aligned with EU market abuse and safe harbour regulations.

When is Genmab’s share buy-back program expected to end?

The share buy-back program is expected to be completed no later than March 31, 2026. Transactions executed from February 18 to 20, 2026 are early stages of this program, which permits repurchases up to a total of 342,130 shares and DKK 725 million in value.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 23.4 KB